MIT Institute Professor Robert Langer Joins Accelrys NanoBiology Initiative Scientific Advisory Committee

Accelrys, Inc. (NASDAQ:ACCL), a leading provider of scientificmodeling and workflow software solutions, announced that Dr. RobertLanger, institute professor in chemical and biomedical engineering atthe Massachusetts Institute of Technology, has joined the ScientificAdvisory Committee (SAC) of the Accelrys NanoBiology Initiative.Providing an international collaborative framework for its members inacademia, government and industry, the Accelrys NanoBiology Initiativewill assess and develop the IT solutions that address criticalchallenges of nanotechnology-enabled pharmaceutical and diagnosticdesign. Offering his technical and scientific guidance, Dr. Langer hasjoined Initiative Chair Dr. Leroy Hood, president of the Institute forSystems Biology, as the second member of the NanoBiology InitiativeSAC.

As nanotechnology is increasingly applied to biomedical researchand product development, powerful modeling, simulation and analyticaltools can enable engineers and scientists to efficiently assess anddevelop those highly complex systems. The Accelrys NanoBiologyInitiative offers members the opportunity to define and prioritize themost critical challenges in this nascent sector and directly influencethe fundamental software solutions. The Initiative will leverageAccelrys' core strengths in life science modeling, materials modeling,informatics, and workflow technology to develop a comprehensiveinfrastructure that can enable predictive design and analysis of noveldrug delivery platforms, as well as the optimization of devices forbiosensing, imaging, and diagnostics.

"The intersection of materials science and biotechnology is in mymind one of the most interesting, dynamic emerging fields today.Broadening our ability to predict and engineer nanotechnology andnanoscale materials at that interface is a critical next step," saidDr. Robert Langer. "As part of the NanoBiology Initiative's efforts,we'll be addressing the challenge of effectively integratingcomputational modeling into the entire interdisciplinary research anddesign process for biomedical science and engineering, shifting thenanobiology R&D paradigm to one of more informed experimentation."

One of only 13 Institute Professors, MIT's highest faculty memberhonor, Dr. Robert Langer has written more than 880 articles and filednearly 550 patents worldwide, more than 180 of which have beenlicensed to pharmaceutical, chemical, biotechnology and medical devicecompanies. Forbes Magazine and Bio World have named Dr. Langer one ofthe 25 most important individuals in biotechnology. Dr. Langer hasalso served as a member of the United States Food and DrugAdministration's SCIENCE Board, the FDA's highest advisory board, from1995 to 2002 and as chairman from 1999 to 2002.

"With Dr. Langer, a preeminent scientist in the field of drugdelivery, joining molecular biology pioneer Dr. Leroy Hood on ourScientific Advisory Committee, our Initiative members have access tosuperb scientific guidance," said Mark Emkjer, president and chiefexecutive officer of Accelrys. "In their advisory roles, these twogreat minds, both leaders at the intersection of nanotech and the lifesciences, will help us address the significant need fornext-generation technology solutions that further research efforts andin turn help our pharmaceutical and biomedical customers bringinnovative products to market as efficiently as possible."

To learn more about the Initiative or register for the upcominginformational US seminar series scheduled August 8-15th in four citiesnationwide visit:http://www.accelrys.com/info/initiatives/nanobio/index.html

About Accelrys

Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software forcomputation, modeling, simulation, and the management and mining ofscientific data used by biologists, chemists and materials scientists,including nanotechnology researchers, for product design, as well asdrug discovery and development. SciTegic, Inc., a wholly ownedsubsidiary of Accelrys, has pioneered a new technology platform called"data pipelining" to process research discovery data withunprecedented flexibility. Accelrys technology and services aredesigned to meet the needs of today's leading research organizations.The company is headquartered in San Diego, California. For moreinformation about Accelrys, visit its website athttp://www.accelrys.com/.

Forward-Looking Statements

This press release contains forward-looking statements forpurposes of the Private Securities Litigation Reform Act of 1995 (the"Act"). Such statements, including statements relating to theNanoBiology Initiative and products resulting therefrom, are subjectto risks and uncertainties including, but not limited to, the risksthat the initiative will not be successful and that it will not resultin the timely or successful development or commercialization ofsoftware, as well as risks relating to market acceptance or demandrelating to the initiative or software, and other risks anduncertainties described in documents Accelrys has filed with theSecurities and Exchange Commission, including its most recent reporton Form 10-K. All forward-looking statements in this document arequalified entirely by the cautionary statements included in thisdocument and such filings. These risks and uncertainties could causeactual results to differ materially from results expressed or impliedby forward-looking statements contained in this document. Theseforward-looking statements speak only as of the date of this document.Accelrys claims the protection of the safe harbor for forward-lookingstatements contained in the Act and, disclaims any intent orobligation to publicly update or revise any forward-looking statementscontained herein to reflect any change in its expectations with regardthereto or any change in events, conditions or circumstances on whichany such statement is based.